Compare RCMT & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | CDXS |
|---|---|---|
| Founded | 1971 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Major Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.7M | 141.8M |
| IPO Year | N/A | 2010 |
| Metric | RCMT | CDXS |
|---|---|---|
| Price | $18.51 | $1.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | 47.0K | ★ 1.2M |
| Earning Date | 03-11-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $309,840,000.00 | $52,932,000.00 |
| Revenue This Year | $16.29 | $15.64 |
| Revenue Next Year | $6.92 | $5.23 |
| P/E Ratio | $10.72 | ★ N/A |
| Revenue Growth | ★ 13.70 | N/A |
| 52 Week Low | $13.18 | $1.12 |
| 52 Week High | $28.27 | $4.46 |
| Indicator | RCMT | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 27.81 | 39.00 |
| Support Level | $17.26 | $1.12 |
| Resistance Level | $21.41 | $1.36 |
| Average True Range (ATR) | 0.74 | 0.12 |
| MACD | -0.32 | -0.01 |
| Stochastic Oscillator | 3.86 | 29.41 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.